

**Human ASXL1 Deficiency Causes Epigenetic Dysfunction, Combined Immunodeficiency and EBV–Associated Hodgkin Lymphoma**

Maggie P Fu<sup>1\*</sup>, Mehul Sharma<sup>2\*</sup>, Sarah M Merrill<sup>3</sup>, Pariya Yousefi<sup>2</sup>, Ryan Tan<sup>2</sup>, Bhavi P Modi<sup>2</sup>, Kate Del Bel<sup>2</sup>, Rebecca J Deyell<sup>4</sup>, Jacob Rozmus<sup>4</sup>, Wingfield Rehmus<sup>2,5</sup>, Kyla J Hildebrand<sup>2</sup>, Elliot James<sup>2</sup>, Géraldine Blanchard-Rohner<sup>2,6</sup>, Susan Lin<sup>2</sup>, Kevin E Shopsowitz<sup>2,7</sup>, Audi Setiadi<sup>7</sup>, Jefferson Terry<sup>7</sup>, Anna F Lee<sup>7</sup>, Britt I Drögemöller<sup>8,9</sup>, Allison Matthews<sup>1,10</sup>, Maja Tarailo-Graovac<sup>1,11</sup>, Laura Sauvé<sup>2,12</sup>, Hana Mitchell<sup>2</sup>, Julie S Prendiville<sup>2,5</sup>, Julie L Maclsaac<sup>1,13</sup>, Kristy Dever<sup>1,13</sup>, David T S Lin<sup>1</sup>, Mandy Meijer<sup>1,13</sup>, Colin J D Ross<sup>9</sup>, Simon R M Dobson<sup>2,12</sup>, Suzanne M Vercauteren<sup>7</sup>, Wyeth W Wasserman<sup>1</sup>, Clara D M van Karnebeek<sup>2,14,15</sup>, Margaret L McKinnon<sup>2,16</sup>, Michael S Kobor<sup>1,13#</sup>, Stuart E Turvey<sup>2#</sup>, Catherine M Biggs<sup>2#</sup>

<sup>1</sup>British Columbia Children's Hospital, Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.

<sup>2</sup>Department of Pediatrics, British Columbia Children's Hospital, The University of British Columbia, Vancouver, BC, Canada.

<sup>3</sup>Department of Psychiatry and Human Behavior, The Warren Alpert Medical School at Brown University, Providence, RI, USA.

<sup>4</sup>Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada.

<sup>5</sup>Divisions of Pediatric Dermatology, Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada.

<sup>6</sup>Unit of Immunology and Vaccinology, Division of General Pediatrics, Dept. of Woman, Child, and Adolescent Medicine, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

<sup>7</sup>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

<sup>8</sup>Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.

<sup>9</sup>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.

<sup>10</sup>Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada.

<sup>11</sup>Alberta Children's Hospital Research Institute, Department of Biochemistry and Molecular Biology and Department of Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

<sup>12</sup>Pediatric Infectious Diseases, Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada.

<sup>13</sup>Edwin S.H. Leong Healthy Aging Program, University of British Columbia, Vancouver, Canada.

<sup>14</sup>Departments of Pediatrics and Human Genetics, Emma Center for Personalized Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

44 <sup>15</sup>Centre for Molecular Medicine and Therapeutics, BC Children's Hospital Research  
45 Institute, Vancouver, Canada.

46 <sup>16</sup>Department of Medical Genetics, University of British Columbia, Vancouver, Canada.

47

48

49 \*These authors contributed equally.

50 #These authors contributed equally.

51

52

53 **Correspondence to:** Catherine M. Biggs, MD, MSc  
54 BC Children's Hospital,  
55 4480 Oak St,  
56 Vancouver, BC, V5Z 4H4, Canada  
57 Phone: 604-875-2118 ext 2  
58 Email: cbiggs@bcchr.ca

59

60 **Word count:** 4068

61

62

63 **ABSTRACT**

64 Inborn errors of immunity (IEI) are a group of disorders caused by deleterious variants  
65 in immune-related genes, including some that function as epigenetic regulators.  
66 Additional sex combs-like 1 (ASXL1) is an epigenetic modifier that has not previously  
67 been linked to an IEI. Somatic *ASXL1* variants are found in clonal hematopoiesis and  
68 hematologic neoplasms, while heterozygous germline variants cause Bohring–Opitz  
69 syndrome. We present a new IEI caused by biallelic germline variants in *ASXL1*. The  
70 patient had a complex and unusual history of disease progression notable for persistent  
71 cutaneous vaccine-strain rubella granulomas initially manifesting in early childhood,  
72 chronic macrocytosis and mild bone marrow cellular hypoplasia, and Epstein Barr virus–  
73 associated Hodgkin lymphoma in adolescence. Detailed immunophenotyping revealed  
74 progressive loss of B-cells, hypogammaglobinemia, and T-cell lymphopenia with severe  
75 skewing toward a memory phenotype and elevated expression of T-cell exhaustion and  
76 senescence markers. Molecular investigations confirmed ASXL1 protein deficiency in  
77 the patient’s T-cells and fibroblasts. The T-cells exhibited marked loss of DNA  
78 methylation, increased epigenetic aging, and CD8 T-cell dysfunction. These aberrations  
79 were ameliorated by lentivirus-mediated transduction with wild-type *ASXL1*, confirming  
80 the pathogenicity of *ASXL1* variants. This study defines a novel human IEI caused by  
81 ASXL1 deficiency, a diagnosis that should be considered in individuals with chronic viral  
82 infections, virus-associated hematologic malignancies, and combined  
83 immunodeficiency. Furthermore, our findings provide fresh insights into the mechanisms  
84 underlying the roles of human ASXL1 in T-cell function as well as in the development  
85 and maintenance of lymphomas.

**86 INTRODUCTION**

87 Monogenic inborn errors of immunity (IEIs) are a group of more than 480 rare diseases  
88 caused by deleterious germline variants in immune-related genes.<sup>1</sup> Some of these IEI  
89 disease-causing variants occur in genes encoding epigenetic regulators that modify  
90 steady-state gene expression and cellular phenotype, such as *DNMT3A* and *TET2*.<sup>2,3</sup>  
91 These alterations in epigenetic regulation disrupt hematopoiesis and cellular  
92 differentiation pathways that are important for immune function,<sup>4,5</sup> giving rise to  
93 inflammation, lymphoproliferation, and increased susceptibility to infections and  
94 cancer.<sup>6,7</sup>

95 Hematologic malignancies account for the majority of cancers in IEIs and are mainly of  
96 lymphoid origin, however, myeloid leukemias and myelodysplastic syndromes (MDS)  
97 also occur.<sup>6</sup> Impaired cell-mediated immunosurveillance, chronic viral infections, and  
98 inflammation contribute to the increased risk and early onset of cancers observed in  
99 IEIs.<sup>8,9</sup> Furthermore, the same mechanisms underlying immunodeficiency in certain IEIs  
100 may also promote oncogenesis in a cell-intrinsic manner, such as DNA repair or  
101 epigenetic defects, causing genomic instability.<sup>9</sup> Somatic variants in IEI-associated  
102 genes are also observed in hematologic malignancies, further supporting their  
103 oncogenic role.<sup>10</sup> Indeed, acquired variants in the epigenetic regulatory genes *DNMT3A*,  
104 *TET2*, and *ASXL1* (DTA mutations) are common in age-related clonal hematopoiesis  
105 and myeloid neoplasms.<sup>11,12,13,14</sup> *ASXL1* (MIM #612990) is the least characterized of the  
106 three DTA genes, and unlike *DNMT3A* and *TET2* has not previously been linked with  
107 immunodeficiency in humans.

108 *ASXL1* comprises part of the Polycomb repressive deubiquitinase (PR-DUB) complex,<sup>15</sup>  
109 which along with Polycomb repressor complexes 1 and 2 (PRC1/2) represses target  
110 genes by modifying chromatin. In embryonic development, establishment of histone  
111 H2A lysine 119 monoubiquitination (H2AK119ub1) by PRC1 is crucial for the  
112 recruitment of PRC2 and corresponding transcriptional repression, and plays a key role  
113 in establishing chromatin bivalency whereby histone modifications associated with  
114 transcriptional activation or repression co-occur.<sup>16,17</sup> The PR-DUB complex removes

115 H2AK119ub1 at later developmental stages to maintain transcriptional  
116 regulation.<sup>16,17,18,19</sup>

117 In keeping with the critical role of PR-DUB in development, *de novo* heterozygous loss-  
118 of-function (LoF) *ASXL1* variants cause the neurodevelopmental disorder Bohring–Opitz  
119 Syndrome (BOS), characterized by severe developmental delay, microcephaly, failure  
120 to thrive, and distinct facial features.<sup>20</sup> While *Asx1*-null mice recapitulate BOS  
121 phenotypes, heterozygous germline deletion and hematopoietic-specific *Asx1* deletion  
122 lead to MDS-like features.<sup>21,22</sup> Mechanistic studies of BOS and ASXL1-associated  
123 hematologic malignancies implicate ASXL1 in differential DNA methylation patterns and  
124 altered epigenetic age.<sup>23,24,25,26</sup> Further, conditional knock-in of an *Asx1* variant  
125 associated with clonal hematopoiesis revealed a phenotype of impaired T-cell  
126 development, function and exhaustion that drove tumor progression in mice.<sup>27,28,29</sup>

127 Here, we report the first patient with an IEI due to biallelic germline variants in *ASXL1*  
128 causing ASXL1 deficiency presenting with combined immunodeficiency complicated by  
129 vaccine-strain rubella virus granulomas and Epstein–Barr virus (EBV)-associated  
130 Hodgkin lymphoma. We characterize the patient's clinical phenotype and treatment  
131 course, and provide a mechanistic study of the epigenetic and immunological impact of  
132 autosomal recessive ASXL1 deficiency. We anticipate that this discovery will empower  
133 the diagnosis and management of additional patients with ASXL1 deficiency.

**134 METHODS****135 Participants and consent**

136 Peripheral blood samples were collected from the index patient and patient's parents  
137 and sibling, as well as three unrelated healthy individuals at the BC Children's Hospital  
138 Research Institute. Similarly, skin biopsies were collected from the patient and six  
139 healthy individuals. All participants from whom we collected biological samples and/or  
140 their parents/guardians provided written informed consent for sample collection,  
141 sequencing, data analysis, and the publication of findings and photographs. Data from  
142 additional samples were obtained from publicly available databases, as outlined below.  
143 The research protocols were approved by the University of British Columbia Clinical  
144 Research Ethics Board (H15-00641).

**145 Identification of candidate variant**

146 Genomic DNA was isolated from peripheral blood using standard procedures and  
147 exome/genome sequencing was performed on the Illumina HiSeq platform (Macrogen,  
148 Seoul, South Korea). Sequencing data were analyzed using an updated version of our  
149 in-house, open-source, semi-automated bioinformatics pipeline as described  
150 previously.<sup>30,31</sup> Trio whole-exome sequencing (trio-WES) was performed on genomic  
151 DNA from the patient and both parents. Compound heterozygous *ASXL1* variants were  
152 considered the top candidates of interest. Additional information on candidate gene  
153 selection is available in the **Supplementary Methods**. Whole-genome sequencing  
154 (WGS) was then performed to scan for potential somatic mosaic variants and to exclude  
155 variants in noncoding regions. Compound heterozygous *ASXL1* variants still emerged  
156 as the variants of highest significance and were further verified by sequencing  
157 (**Supplementary Methods**).

**158 Generation and maintenance of patient's primary T-cells and fibroblasts**

159 For generation of T-cell blasts, T-cells were isolated from peripheral blood mononuclear  
160 cells (PBMCs) (EasySep™ Human T-Cell Isolation Kit, Cat # 17951; Stemcell,  
161 Vancouver, BC, Canada) and activated for 12 days (**Supplementary Methods**).

162 To generate fibroblasts, a skin biopsy was obtained, manually cut into smaller pieces,  
163 and placed in separate wells of a 6-well plate in complete DMEM (GE Healthcare,  
164 Chicago, IL, USA) until formation of a confluent fibroblast monolayer (**Supplementary**  
165 **Methods**).

#### 166 **Stable WT ASXL1 expression in expanded patient-derived T-cells**

167 Stable wild-type (WT) ASXL1 expression was achieved by infection of expanded  
168 patient-derived T-cells with lentiviral particles as described previously,<sup>32,33</sup> and  
169 expanded cells were used for downstream DNA methylation and intracellular flow  
170 cytometric analyses (**Supplementary Methods**).

#### 171 **DNA methylation array**

172 Blood and buccal swabs were collected from the index patient, and genomic DNA was  
173 extracted from whole blood (WB), PBMCs, buccal cells, and cultured T-cells. Aliquots of  
174 160 ng of extracted DNA (750 ng) subjected to bisulfite conversion (EZ-96 DNA  
175 Methylation kit; Zymo Research, Irvine, CA, USA) were assayed. DNA extracted from  
176 primary tissues and T-cells was assayed using Infinium HumanMethylationEPIC  
177 BeadChip (EPIC) and HumanMethylationEPICv2 BeadChip arrays (Illumina, San Diego,  
178 CA, USA), respectively. Two patient PBMC samples were prepared and assayed as  
179 technical replicates on the EPIC arrays. (**Supplementary Methods**).

#### 180 **Sample selection for pediatric population reference set**

181 To establish a pediatric population reference set, publicly available DNAm microarray  
182 data on blood and buccal samples were downloaded from the Gene Expression  
183 Omnibus (GEO) database, including both EPIC arrays and their predecessors, the  
184 Illumina Infinium HumanMethylation450 BeadChip (450k) arrays. We filtered for healthy

185 control (HC) samples with the cohorts and sample selection outlined in the  
186 **Supplementary Methods**. The cohorts and demographics are described in  
187 **Supplementary Table 1-3**. Details of normalization, quality control, and imputation of  
188 the HC and patient samples are also presented in the **Supplementary Methods**.

### 189 **Epigenetic age analysis**

190 The index patient, family control, and unrelated HC blood, buccal, and T-cell epigenetic  
191 age were estimated with the Horvath pan-tissue clock,<sup>34</sup> Hannum clock,<sup>35</sup> and Horvath  
192 skin and blood clock<sup>36</sup> using the `methylock` R package (**Supplementary Methods**).

### 193 **Differential DNA methylation analysis**

194 Cell-type proportion prediction, subsequent accounting for intersample cellular  
195 heterogeneity, and adjusting for other sources of batch effects were performed prior to  
196 differential methylation analysis as presented in the **Supplementary Methods**. For  
197 differential DNA methylation analysis, linear regression were performed with `limma`.<sup>37</sup>  
198 For each primary tissue, the regression model accounted for sex and age, whereas for  
199 cultured T-cells we additionally accounted for batch and CD8 T-cell proportion  
200 measured by flow cytometry. Details of the regression model are presented in the  
201 **Supplementary Methods**. Multiple test correction was performed with the Benjamini-  
202 Hochberg procedure<sup>38</sup>. Skewness of the differential DNAm pattern was assessed with  
203 skewness test for normality, implemented with `skewness.norm.test` function in the  
204 `normtest` package.<sup>39</sup>

### 205 **Enrichment analysis**

206 Overrepresentation analyses were performed to identify enriched ChromHMM  
207 chromatin states with the `gometh` function in the `missMethyl` package  
208 (**Supplementary Methods**).

### 209 **Intracellular flow cytometry in PBMCs, expanded T-cells, and primary fibroblasts**



210 Intracellular flow cytometry was performed to examine the expression of ASXL1,  
211 H2AK119ub1, and IL-2-induced phospho-STAT5 (pSTAT5) in expanded patient-  
212 derived primary T-cells; pSTAT5 in PBMCs; and ASXL1 in primary fibroblasts  
213 **(Supplementary Methods).**

#### 214 **Clinical-grade flow cytometry**

215 Immunophenotyping of clinical samples was performed using WB at an accredited  
216 clinical flow cytometry laboratory following established standard protocols  
217 **(Supplementary Methods).**

#### 218 **Histology**

219 Formalin-fixed, paraffin-embedded lymph node tissue was cut into sections 3 µm thick  
220 for routine hematoxylin and eosin (H&E) staining or 5 µm thick for  
221 immunohistochemistry. Bone marrow trephine biopsies were processed in B-plus  
222 solution followed by decalcification and formalin fixation. Paraffin embedded marrow  
223 tissue was then cut into sections 3 µm thick for routine hematoxylin and eosin (H&E)  
224 staining or 4 µm thick for immunohistochemistry.

#### 225 **Data availability**

226 The data is available upon request by emailing the corresponding author.

227 **RESULTS**228 **Case description**

229 The index patient is currently an adolescent female (10 to 19 years of age) born to  
230 nonconsanguineous parents. One parent has a history of rheumatoid arthritis, while the  
231 other parent and sibling have no notable clinical history. The index patient was born full-  
232 term and received all routine immunizations, including live attenuated measles, mumps,  
233 rubella (MMR) vaccine (**Fig. 1A**). During early childhood (0 to 5 years of age), she  
234 developed chronic ulcerated skin granulomas on the right arm and left leg. She was  
235 hospitalized twice for pneumonia between 0 to 10 years of age, with the latter in the  
236 context of primary EBV infection. Laboratory tests over time showed chronic  
237 macrocytosis, T-cell lymphopenia, progressive loss of B-cells, and  
238 hypogammaglobulinemia (**Fig. 1B, Supp. Fig. 1B**).

239 Despite prolonged systemic courses of antimicrobials, topical corticosteroids and wound  
240 care, the skin granulomas persisted for more than a decade, with new lesions  
241 developing in the left inguinal region. Repeated biopsies showed necrotizing  
242 granulomatous inflammation with no organisms identified on special stains. (**Fig. 1C,**  
243 **Supp. Fig. 1C**). Serial bone marrow biopsies every 1–2 years showed mild  
244 hypocellularity, megaloblastoid changes, and eventually the presence of non-necrotizing  
245 granulomas (**Fig. 1D**). Infectious studies revealed intermittent EBV viremia (ranging  
246 from 0 to 1000s copies/mL), absent antibody titers to measles, mumps, varicella, and  
247 hepatitis B, but high titers to rubella. A biopsy from one of the cutaneous granulomas  
248 was tested for vaccine-strain rubella, RA 27/3, and was found to be positive by  
249 polymerase chain reaction.

250 In early adolescence (10 to 15 years of age), the patient was diagnosed with EBV-  
251 associated stage IVA classical Hodgkin lymphoma, mixed cellularity subtype with  
252 prominent granulomatous inflammation (**Supp Fig 1D and Supplementary Clinical**  
253 **Data**). She underwent four cycles of chemotherapy, at which time a repeat Positron  
254 Emission Topography (PET)-CT showed progressive disease, and she was transitioned  
255 to nivolumab, anti- programmed cell death protein 1 (PD1) antibody, immunotherapy.

256 This was complicated by the development of autoimmune thyroiditis treated with  
257 thyroxine. Six weeks following discontinuation of nivolumab, conditioning was begun for  
258 a 9/10 matched unrelated donor hematopoietic stem cell transplant (HSCT) with  
259 cyclophosphamide, fludarabine and 200cGy total body irradiation. She received  
260 mycophenolate mofetil and tacrolimus prophylaxis for graft versus host disease (GVHD)  
261 and developed grade 1 GVHD of upper gut and skin which was treated with  
262 corticosteroids. She was discharged on day +34 with full donor chimerism, and remains  
263 well now 6 months posttransplant with healing of her chronic skin lesions.

264 **Identification and characterization of novel germline compound heterozygous**  
265 **ASXL1 variants in the index patient**

266 Given the unique clinical presentation and the severity of the clinical phenotype, trio-  
267 WES and subsequent WGS were performed. Sequencing results identified compound  
268 heterozygous variants in *ASXL1*, a maternally inherited variant in exon 5 (Var1:  
269 NM\_015338.6:c.332G>A;NP\_056153.2:p.Cys111Tyr) and a paternally inherited variant  
270 in exon 13 (Var 2: NM\_015338.6:c.3710C>T;NP\_056153.2:p.Ser1237Phe), as  
271 candidates. Sequencing confirmed that the biallelic *ASXL1* variants segregated with the  
272 presence of disease in the family (**Fig. 2A,B**). These are missense variants predicted to  
273 be deleterious, and were considered to be strong candidates for further functional  
274 evaluation based on their changes in amino acid polarities, high combined annotation-  
275 dependent depletion (CADD) scores (Var1: 26.2; Var 2: 23.0), and their low allelic  
276 frequency in the Genome Aggregation Database (gnomAD) v3 (Var1: 8.12e-06; Var2:  
277 1.22e-05, with no homozygotes for either variant; **Supp. Fig. 2A**). Both variants fell  
278 outside the mutation hotspot region associated with typical truncating BOS variants in  
279 *ASXL1* exon 13 (**Fig. 2C**).

280 Molecular consequences of the patient's *ASXL1* variants were investigated next.  
281 Expanded patient primary T-cells (both CD4 and CD8) expressed approximately half the  
282 amount of total ASXL1 protein when compared to both healthy controls (HCs) and  
283 family members ( $p < 0.05$ , **Fig 2D**). ASXL1 deficiency was also confirmed in patient  
284 cultured fibroblasts obtained from a skin biopsy (**Fig. 2E**). Given the well-described role

285 of ASXL1 in H2AK119 deubiquitination,<sup>40</sup> we quantified H2AK119ub1 in expanded T-  
286 cells but did not find notable differences in bulk enrichment levels between the patient  
287 and controls (**Fig. 2F**). While surprising, recent work has shown that BOS-causing  
288 germline *ASXL1* variants do not alter specific histone modifications, including  
289 H2AK119ub1, but rather cause DNAm dysregulation.<sup>23</sup> Therefore, we next assessed the  
290 global DNAm signatures in the patient.

### 291 **Differential DNAm in PRC-regulated genomic elements and advanced epigenetic** 292 **aging in the patient's lymphocytes**

293 We conducted epigenome-wide association studies (EWAS) to compare the DNAm  
294 patterns of primary patient samples to age-matched HCs compiled from publicly  
295 available data sets in three tissue types: buccal swabs ( $n = 725$ ), whole blood (WB) ( $n =$   
296  $452$ ), and isolated PBMCs ( $n = 285$ ). We observed wide-spread differential DNAm  
297 between the patient and HCs in WB and PBMCs (**Fig. 3A**) but not in buccal swabs  
298 (**Supp. Fig. 3A**). There were 50 885 differentially methylated sites (DMs) in WB, 18 581  
299 DMs in PBMCs, but only 38 DMs in buccal swabs that passed the threshold of adjusted  
300  $P$ -value ( $P_{adj} \leq .05$ , 15.7% of which (9438 DMs) overlapped between WB and PBMCs  
301 (**Fig. 3B**). Emphasizing that this patient does not have BOS, we found that BOS-  
302 associated DMs were not enriched in our analysis (**Supp. Fig. 3B**). Pathway enrichment  
303 analysis with 18-state ChromHMM chromatin state annotation showed that DMs in both  
304 WB and PBMCs were significantly enriched in regulatory elements, such as enhancers,  
305 bivalent transcription start sites, and repressed Polycomb regions, as well as some  
306 quiescent gene and heterochromatin regions in PBMCs (**Fig. 3C**).

307 To gain further information about the patient's DNA methylome, we assessed the  
308 patient's tissue-specific EA. In analysis of buccal swabs, the patient was estimated to  
309 have a pediatric buccal epigenetic (PedBE) clock age of 10 to 15 years, matching her  
310 actual age of 10 to 15 years at sample collection (**Supp. Fig. 3C**). In contrast, the  
311 Horvath pan-tissue age of blood samples was higher compared to her chronological age  
312 (**Fig. 3D**). Similarly, the predicted telomere length based on DNAm data was also lower  
313 in blood (**Fig. 3D**), and the presence of short telomeres in lymphocytes and

314 granulocytes was confirmed by direct measurement (**Supp. Fig. 3D**). Overall, the  
315 ASXL1-deficient patient had increased EA and short telomeres compared to HC, which  
316 was especially prominent in lymphocyte subsets.

317 **Wide-spread DNAm loss and advanced epigenetic aging in patient's T-cells were**  
318 **rescued by WT ASXL1 transduction**

319 We transduced expanded patient-derived T-cells with WT *ASXL1* to delineate the  
320 relations between the patient's variants and the alterations in epigenetic regulation in  
321 lymphocytes. Whereas empty vector (EV)-transduced patient cells (patient condition)  
322 maintained a lower ASXL1 protein level compared to the EV-transduced HC cells (HC  
323 condition), WT *ASXL1*-transduced patient cells (rescued condition) showed increased  
324 ASXL1 protein comparable to the HC condition (**Fig. 4A**).

325 Principal component analysis (PCA) of the T-cells' DNAm showed that the patient  
326 clustered away from the HC (including family member) cells along PC2, with the  
327 rescued cells in the middle (**Fig. 4B**). Analysis of the *patient vs. HC* comparison yielded  
328 141 113 differentially methylated sites (DMs) ( $P_{\text{adj}} < .2$  and  $\Delta\beta > 0.1$ ), of which  
329 129,104 (91.5%) showed decreased DNAm. The pattern observed in the PCA plot was  
330 replicated in the DMs—patient samples were notable for their decreased DNAm, while  
331 the rescued condition showed an intermediate DNAm level (**Fig. 4C**). Furthermore, loss  
332 of DNAm in the patient condition occurred mainly in loci that were highly methylated in  
333 HC samples; of the DMs with decreased DNAm, 80.1% were > 50% methylated in the  
334 HCs (skewness test  $P < 2.2e-16$ , **Fig. 4C**). In the *rescued vs. HC* condition, 35 457  
335 DMs were identified, and 90 354 of the *patient vs. HC* DMs were not significantly  
336 different in this comparison, indicating that the majority of the DMs in the patient's cells  
337 were rescued by WT *ASXL1* transduction (**Fig. 4D**). Similar to our findings in blood, the  
338 genomic locations of DMs were highly enriched for repressed Polycomb and bivalent  
339 chromatin states, with the rescued cells showing higher  $P$ -values than that of patient  
340 cells (**Fig. 4D,E**).

341 We also investigated epigenetic aging in this context. For the controls, the Horvath pan-  
342 tissue clock slightly underpredicted chronological age. In contrast, the clock assigned

343 the patient an epigenetic age on average 27.4 years older than her chronological age,  
344 and WT *ASXL1* lowered her epigenetic age (**Fig. 4F**). Specifically, the difference  
345 between epigenetic and chronological age was significantly higher in the patient than  
346 family and unrelated HCs, and this difference was significantly reduced by WT *ASXL1*  
347 ( $P < .0005$ ) (**Fig. 4F**). Other epigenetic clocks corroborated the trend (**Supp. Fig. 4A,B**).  
348 Overall, WT *ASXL1* transduction rescued the DNAm differences and attenuated the  
349 advanced epigenetic aging driven by the patient's *ASXL1* variants.

### 350 ***ASXL1* variants caused impaired CD4 and CD8 T-cell maintenance and activation**

### 351 **in patient primary cells**

352 Given the methylation impairments in patient T-cells, we conducted detailed  
353 immunophenotyping of peripheral blood prior to the patient's lymphoma diagnosis.  
354 Naïve CD4 and CD8 T-cell subsets and recent thymic emigrants were markedly  
355 reduced, suggesting poor thymic output (**Fig. 5A, Table 1**). The patient showed  
356 expansion of PD1<sup>+</sup> CD4 and CD8, and CD57<sup>+</sup> CD8 T-cell populations (**Fig. 5A**),  
357 indicating T-cell exhaustion and senescence. CD8 T-cells had a restricted T-cell  
358 receptor repertoire (**Table 1**). We then assessed pSTAT5 signaling and reactive oxygen  
359 species (ROS) production, as alterations in these pathways were reported in T-cells  
360 containing an *ASXL1* variant associated with clonal hematopoiesis of indeterminate  
361 potential.<sup>29</sup> We observed significantly increased pSTAT5 abundance after low-dose IL-2  
362 (10U/mL) treatment in naïve CD8 T-cells (**Fig 5B**) but no difference in the memory T-  
363 cell compartment (**Supp Fig 5A-B**). Reduced pSTAT5 production was observed in  
364 expanded patient CD8 T-cells after IL-2 treatment, which was rescued by stable WT  
365 *ASXL1* expression, indicating a causative role for *ASXL1* in regulating STAT5-mediated  
366 CD8 T-cell homeostasis (**Fig 5C**). Finally, high ROS production was observed in  
367 expanded patient CD4 T-cells, which was rescued upon transduction of WT *ASXL1*  
368 (**Supp Fig 5C**), suggesting alternative modes of *ASXL1* variant-mediated impairments  
369 of CD4 and CD8 T-cells.

370 **DISCUSSION**

371 Here, we reported the clinical, epigenetic, and biochemical findings of the first case of  
372 autosomal recessive ASXL1 deficiency in a female with combined immunodeficiency  
373 and EBV-associated Hodgkin lymphoma. Single-patient studies account for  
374 approximately one-third of newly identified monogenic immune disorders,<sup>1</sup> requiring  
375 methodical validation to establish causality. Following the guidelines proposed by  
376 Casanova *et al.* for studies in single patients,<sup>41</sup> we showed that the *ASXL1* variants  
377 identified in the patient are rare, monogenic, and have complete penetrance. Studies in  
378 primary patient cells demonstrated decreased ASXL1 protein levels, dysregulated  
379 DNAm, and epigenetic age acceleration. Finally, we showed that epigenetic and  
380 immunological defects in the patient's cells were rescued by transduction of WT *ASXL1*.  
381 The patient's rare and severe clinical presentation provided further support for an  
382 underlying genetic cause.<sup>41</sup> She had a combined immunodeficiency, with T-cell  
383 lymphopenia from early childhood followed by progressive loss of B-cells. After  
384 receiving live MMR vaccine, she developed vaccine-strain rubella-positive granulomas.

385

386 From a hematology/oncology perspective, she had persistent macrocytosis and mild  
387 bone marrow hypocellularity, and developed chemorefractory advanced Hodgkin  
388 lymphoma. Based on our findings, patients presenting with this unique clinical profile  
389 should be evaluated for autosomal recessive ASXL1 deficiency.

390 Epigenome-wide association studies (EWAS) showed significant alterations of DNAm in  
391 patient T-cells, PBMCs, and WB, but not buccal swabs; DNAm decreased  
392 predominately in T-cells and WB, but was increased in PBMCs. The contrasting  
393 significance and directionality of EWAS results across tissue types suggests cell type-  
394 specific impacts of the *ASXL1* variants on global DNAm. This was further supported by  
395 the observation of pronounced increase in epigenetic age and reduced telomere length  
396 exclusively in lymphocytes. Global hypomethylation and focal hypermethylation are key  
397 features of aging, as epigenetic marks are ineffectively maintained through S phase of  
398 mitosis.<sup>42</sup> We showed the patient's *ASXL1* LoF variants drive epigenetic features with  
399 DNAm loss and increased epigenetic age in T-cells. This is supported by recent findings

400 showing altered chromatin accessibility and DNAm inhibition in *ASXL1* KO CD8 T-  
401 cells<sup>43</sup>, and high epigenetic age differences in BOS patients with *ASXL1* truncation  
402 variants<sup>24</sup>, highlighting the role of *ASXL1* on cellular aging.

403 Our detailed molecular and clinical evaluation of human *ASXL1* deficiency provides  
404 further insight into the role of immune dysregulation in cancer predisposition. Global  
405 hypomethylation has also been proposed to act as a replicative barrier against highly  
406 proliferative and premalignant cells by inducing cellular senescence.<sup>44,45</sup> In this case,  
407 however, T-cell senescence may have played a role in impaired antiviral and antitumor  
408 immunity, contributing to the development of EBV-associated Hodgkin lymphoma.<sup>46</sup>  
409 Indeed, recent modeling of an *ASXL1* variant associated with clonal hematopoiesis  
410 showed that it promoted the progression of solid tumors via impaired intrathymic T-cell  
411 development, naïve-memory T-cell imbalance, and T-cell exhaustion<sup>29</sup>. Loss of *Asx1*  
412 and overexpression of truncated *Asx1* in mice also lead to limited hematopoietic stem  
413 cell self-renewal capacity and decreased peripheral lymphocyte numbers.<sup>22,29,47,48</sup>  
414 Consistent with these findings, we also observed the near-absence of recent thymic  
415 emigrants and naïve T-cells, combined with T-cell exhaustion in the patient. The altered  
416 epigenetic and immune landscape, advanced cellular aging, CD8 T-cell senescence,  
417 and T-cell exhaustion in the context of chronic infection likely all contribute to an  
418 oncogenic environment. Some of these mechanisms may also play roles in other  
419 hematopoietic malignancies, specifically acute myeloid leukemia, chronic  
420 myelomonocytic leukemia, and MDS,<sup>49,50,51</sup> where somatic *ASXL1* variants are  
421 commonly described.<sup>49</sup> Taken together, *ASXL1* LoF variants may drive the maintenance  
422 of a protumor milieu.

423 The granulomas that emerged in early childhood (0 to 5 years of age) represented a  
424 particularly enigmatic feature of this patient's clinical course. These lesions persisted for  
425 more than a decade, were refractory to treatment, and were labeled as idiopathic until  
426 recognized as positive for vaccine-strain rubella virus. Rubella virus was first identified  
427 in the granulomas of three IEI patients in 2014,<sup>52</sup> and are now linked to ~60% of  
428 idiopathic cutaneous granulomas in IEIs. Rubella granulomas have been typically found



429 in individuals with ataxia telangiectasia and other related DNA repair disorders.<sup>53,54,55,56</sup>  
430 Our study adds to this relatively new field by suggesting dysregulation of an epigenetic  
431 modifier, *ASXL1*, as a cause of vaccine-strain rubella-associated granuloma. The  
432 profound T-cell impairments and deficiency described here represent possible  
433 underlying mechanisms, as defective T-cell cytotoxicity has been implicated in rubella  
434 vaccine-associated granulomas.<sup>56</sup> Further studies are needed to elucidate the  
435 immunological basis of this rare and serious complication.<sup>56</sup>

436 Heterozygous germline truncating variants of *ASXL1* are known to cause the  
437 neurodevelopmental disorder BOS.<sup>57</sup> The hematologic and immune disorder described  
438 here was distinct from BOS in both its molecular and clinical effects. We identified  
439 biallelic missense *ASXL1* variants located outside the mutational hotspot associated  
440 with BOS. The DNAm signature in our patient also does not overlap with that seen in  
441 BOS patients<sup>24</sup>. A recent study further showed no impairment of ASXL1 protein level in  
442 BOS patients, contrasting our findings.<sup>23</sup> Studies in mouse models indicated that  
443 *Asxl1*<sup>-/-</sup> mice show developmental abnormalities and failure to thrive, recapitulating  
444 elements of the BOS patient phenotype,<sup>22,47</sup> while *Asxl1*<sup>-/+</sup> mice develop an MDS-like  
445 phenotype possibly attributable to *Asxl1* haploinsufficiency.<sup>22</sup> Given these findings,  
446 BOS-causing *ASXL1* variants likely have different functional impacts than those in our  
447 patient, which may contribute to the distinct phenotype observed. Future studies directly  
448 comparing samples from patients with autosomal recessive ASXL1 deficiency to those  
449 with BOS may further elucidate the mechanistic differences between these two  
450 diseases.

451 This study had many strengths, notably the detailed clinical and immunological  
452 description of the first human case of biallelic ASXL1 deficiency and well-controlled  
453 epigenetic profiling with family controls and a population reference data set across  
454 multiple tissues. However, there were also limitations. First, this was a single-patient  
455 study, and ultimately the full phenotype of human ASXL1 deficiency will only be defined  
456 through diagnosis of more patients. Second, while we observed global differential  
457 DNAm in patient whole blood and PBMCs, we explored the effect of WT *ASXL1*

458 transduction only in patient T-cells. Sample limitations restricted us from working on  
459 other cell types (eg, neutrophils) in a controlled setting. Similar to previous findings, we  
460 showed the effects of *ASXL1* variants to be highly cell type-specific,<sup>48</sup> and therefore  
461 examining different cellular models could elucidate the roles of ASXL1 in hematopoiesis  
462 and disease. Finally, although our patient has benefitted clinically from allogeneic  
463 HSCT, follow-up was only 6 months at the time of writing, so the observed benefits  
464 should be interpreted with caution.

465

466 In conclusion, our study identified a novel human ICI caused by germline biallelic  
467 deleterious *ASXL1* variants. These observations will empower diagnosis of future  
468 patients with ASXL1 deficiency, and expand the clinical spectrum of disease associated  
469 with LoF *ASXL1*. We recommend genetic testing at the first sign of combined immune  
470 deficiency as a powerful precision medicine approach to guide diagnosis and inform  
471 therapeutic decision-making processes.

472 **Acknowledgements:** We are grateful to our colleagues, Karlie Edwards, Chaini Konwar,  
473 Hilary Brewis, Hannah-Ruth Engelbrecht, and Alan Kerr, who critically contributed to the  
474 flow and style of the manuscript. Thanks are also due to Nicole Gladish who facilitated  
475 the downloading and merging of ChromHMM data from the Roadmap Epigenomics  
476 database. We are also grateful for the help in patient management and organization of  
477 the investigation effort we received from Anne K Junker.

478 **Funding:** This work was supported by grants from the Canadian Institutes of Health  
479 Research (EGM-141897) (M.S.K.) (PJT-178054) (S.E.T., C.M.B.), Genome British  
480 Columbia (SIP007) (S.E.T.), Michael Smith Health Research BC (HPI-2018-2014)  
481 (C.M.B.) and BC Children's Hospital Foundation. M.S.K. is the Edwin S.H. Leong UBC  
482 Chair in Healthy Aging, C.M.B. is a MSHRBC Health Professional-Investigator, and S.E.T.  
483 holds a Tier 1 Canada Research Chair in Pediatric Precision Health and the Aubrey J.  
484 Tingle Professor of Pediatric Immunology.

485 **Contribution:** Contribution described using the CRediT taxonomy.

486 Contributions=Conceptualization, Methodology, Formal Analysis, Investigation,  
487 Visualization, Writing-original draft preparation, Writing-reviewing and editing (Maggie P  
488 Fu, Mehul Sharma).

489 Contributions= Investigation, Resources, Writing-reviewing and editing (Sarah Merrill,  
490 Pariya Yousefi, Ryan Tan, Bhavi P Modi, Kate Del Bel, Rebecca J Deyell, Jacob  
491 Rozmus, Wingfield Rehmus, Kyla J Hildebrand, Elliot James, Géraldine Blanchard-  
492 Rohner, Susan Lin, Kevin E Shopsowitz, Audi Setiadi, Jefferson Terry, Anna F Lee, Britt  
493 I Drögemöller, Allison Matthews, Maja Tarailo-Graovac, Laura Sauvé, Hana Mitchell,  
494 Julie S Prendiville, Julie L Maclsaac, Kristy Dever, David T S Lin, Mandy Meijer, Colin J  
495 D Ross, Simon R M Dobson, Suzanne M Vercauteren, Wyeth W Wasserman, Clara D  
496 M van Karnebeek, Margaret L McKinnon).

497 Contributions=Conceptualization, Methodology, Investigation, Validation, Visualization,  
498 Resources, Funding acquisition, Project administration, Supervision, Writing-original

499 draft preparation, Writing-reviewing and editing (Michael S Kobor, Stuart E. Turvey,  
500 Catherine M Biggs).

501 **Conflict of Interest Disclosures:** The authors report no conflicts of interest in relation  
502 to this manuscript.

## 503 REFERENCES

- 504 1. Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022  
505 update on the classification from the International Union of Immunological Societies  
506 Expert Committee. *J. Clin. Immunol.* 2022;42(7):1473–1507.
- 507 2. Romano R, Cillo F, Moracas C, et al. Epigenetic alterations in inborn errors of  
508 immunity. *J. Clin. Med.* 2022;11(5):.
- 509 3. Fu MP, Merrill SM, Sharma M, et al. Rare diseases of epigenetic origin: Challenges  
510 and opportunities. *Front. Genet.* 2023;14:1113086.
- 511 4. Izzo F, Lee SC, Poran A, et al. DNA methylation disruption reshapes the  
512 hematopoietic differentiation landscape. *Nat. Genet.* 2020;52(4):378–387.
- 513 5. Campos-Sanchez E, Martinez-Cano J, Del Pino Molina L, Lopez-Granados E,  
514 Cobaleda C. Epigenetic deregulation in human primary immunodeficiencies. *Trends*  
515 *Immunol.* 2019;40(1):49–65.
- 516 6. Haas OA. Primary immunodeficiency and cancer predisposition revisited: embedding  
517 two closely related concepts into an integrative conceptual framework. *Front. Immunol.*  
518 2018;9:3136.
- 519 7. Stremenova Spegarova J, Lawless D, Mohamad SMB, et al. Germline TET2 loss of  
520 function causes childhood immunodeficiency and lymphoma. *Blood.* 2020;136(9):1055–  
521 1066.
- 522 8. Tiri A, Masetti R, Conti F, et al. Inborn errors of immunity and cancer. *Biology.*  
523 2021;10(4):.
- 524 9. Hauck F, Voss R, Urban C, Seidel MG. Intrinsic and extrinsic causes of malignancies  
525 in patients with primary immunodeficiency disorders. *J. Allergy Clin. Immunol.*  
526 2018;141(1):59-68.e4.
- 527 10. Leeksa OC, de Miranda NF, Veelken H. Germline mutations predisposing to  
528 diffuse large B-cell lymphoma. *Blood Cancer J.* 2017;7(2):e532.
- 529 11. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis  
530 associated with adverse outcomes. *N. Engl. J. Med.* 2014;371(26):2488–98.
- 531 12. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-  
532 cancer risk inferred from blood DNA sequence. *N. Engl. J. Med.* 2014;371(26):2477–87.
- 533 13. Zink F, Stacey SN, Norddahl GL, et al. Clonal hematopoiesis, with and without  
534 candidate driver mutations, is common in the elderly. *Blood.* 2017;130(6):742–752.
- 535 14. Shlush LI. Age-related clonal hematopoiesis. *Blood.* 2018;131(5):496–504.
- 536 15. Kassis JA, Kennison JA, Tamkun JW. Polycomb and trithorax group genes in  
537 *Drosophila*. *Genetics.* 2017;206(4):1699–1725.
- 538 16. Li R, Huang D, Zhao Y, et al. PR-DUB safeguards Polycomb repression through  
539 H2AK119ub1 restriction. *Cell Prolif.* 2023;
- 540 17. Macrae TA, Fothergill-Robinson J, Ramalho-Santos M. Regulation, functions and  
541 transmission of bivalent chromatin during mammalian development. *Nat. Rev. Mol. Cell*  
542 *Biol.* 2023;24(1):6–26.
- 543 18. Kasinath V, Beck C, Sauer P, et al. JARID2 and AEBP2 regulate PRC2 in the  
544 presence of H2AK119ub1 and other histone modifications. *Science.*  
545 2021;371(6527):eabc3393.

- 546 19. Bonnet J, Boichenko I, Kalb R, et al. PR-DUB preserves Polycomb repression by  
547 preventing excessive accumulation of H2Aub1, an antagonist of chromatin compaction.  
548 *Genes Dev.* 2022;36(19–20):1046–1061.
- 549 20. Bedoukian E, Copenheaver D, Bale S, Deardorff M. Bohring-Opitz syndrome  
550 caused by an ASXL1 mutation inherited from a germline mosaic mother. *Am. J. Med.*  
551 *Genet. A.* 2018;176(5):1249–1252.
- 552 21. Abdel-Wahab O, Gao J, Adli M, et al. Deletion of *Asxl1* results in myelodysplasia  
553 and severe developmental defects in vivo. *J. Exp. Med.* 2013;210(12):2641–2659.
- 554 22. Wang J, Li Z, He Y, et al. Loss of *Asxl1* leads to myelodysplastic syndrome-like  
555 disease in mice. *Blood.* 2014;123(4):541–553.
- 556 23. Lin I, Wei A, Awamleh Z, et al. Multiomics of Bohring-Opitz syndrome truncating  
557 ASXL1 mutations identify canonical and noncanonical Wnt signaling dysregulation. *JCI*  
558 *Insight.* 2023;8(10):.
- 559 24. Awamleh Z, Chater-Diehl E, Choufani S, et al. DNA methylation signature  
560 associated with Bohring-Opitz syndrome: a new tool for functional classification of  
561 variants in ASXL genes. *Eur. J. Hum. Genet.* 2022;30(6):695–702.
- 562 25. Nischal S, Bhattacharyya S, Christopheit M, et al. Methylome profiling reveals distinct  
563 alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.  
564 *Cancer Res.* 2013;73(3):1076–85.
- 565 26. Rahmani NE, Ramachandra N, Sahu S, et al. ASXL1 mutations are associated with  
566 distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.  
567 *Blood Cancer J.* 2021;11(9):157.
- 568 27. Shi H, Yamamoto S, Sheng M, et al. ASXL1 plays an important role in  
569 erythropoiesis. *Sci. Rep.* 2016;6:.
- 570 28. Fang X, Xu S, Zhang Y, et al. *Asxl1* C-terminal mutation perturbs neutrophil  
571 differentiation in zebrafish. *Leukemia.* 2021;35(8):2299–2310.
- 572 29. Liu X, Sato N, Shimozato Y, et al. CHIP-associated mutant ASXL1 in blood cells  
573 promotes solid tumor progression. *Cancer Sci.* 2022;113(4):1182–1194.
- 574 30. Tarailo-Graovac M, Shyr C, Ross CJ, et al. Exome sequencing and the  
575 management of neurometabolic disorders. *N. Engl. J. Med.* 2016;374(23):2246–55.
- 576 31. van Kuilenburg ABP, Tarailo-Graovac M, Richmond PA, et al. Glutaminase  
577 deficiency caused by short tandem repeat expansion in *GLS*. *N. Engl. J. Med.*  
578 2019;380(15):1433–1441.
- 579 32. Kutner RH, Zhang XY, Reiser J. Production, concentration and titration of  
580 pseudotyped HIV-1-based lentiviral vectors. *Nat. Protoc.* 2009;4(4):495–505.
- 581 33. Sharma M, Fu MP, Lu HY, et al. Human complete NFAT1 deficiency causes a triad  
582 of joint contractures, osteochondromas, and B cell malignancy. *Blood.* 2022;
- 583 34. Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol.*  
584 2013;14(10):.
- 585 35. Hannum G, Guinney J, Zhao L, et al. Genome-wide methylation profiles reveal  
586 quantitative views of human aging rates. *Mol. Cell.* 2013;49(2):359–367.
- 587 36. Horvath S, Oshima J, Martin GM, et al. Epigenetic clock for skin and blood cells  
588 applied to Hutchinson Gilford Progeria Syndrome and ex vivo studies. *Aging.*  
589 2018;10(7):1758–1775.

- 590 37. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses  
591 for RNA-sequencing and microarray studies. *Nucleic Acids Res.* 2015;43(7):e47.
- 592 38. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and  
593 powerful approach to multiple testing. *J. R. Stat. Soc. series B (Methodological)*.  
594 1995;57(1):289-300.
- 595 39. Shapiro SS, Wilk MB, Chen HJ. A comparative study of various tests for normality.  
596 *JASA.* 1968;63(324):1343-72.
- 597 40. Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase  
598 activity of the Polycomb repressive complex PR-DUB. *Nature.* 2010;465(7295):243–7.
- 599 41. Casanova JL, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines for  
600 genetic studies in single patients: lessons from primary immunodeficiencies. *J. Exp.*  
601 *Med.* 2014;211(11):2137–49.
- 602 42. Sen P, Shah PP, Nativio R, Berger SL. Epigenetic mechanisms of longevity and  
603 aging. *Cell.* 2016;166(4):822–839.
- 604 43. Kang TG, Lan X, Alli S, O'Connell CL et al. ASXL1 disruption preserves CD8 T cell  
605 exhaustion-progenitor epigenetic programming during chronic stimulation. *J. Immun.*  
606 2023;210(1\_Supplement):226-10.
- 607 44. Cruickshanks HA, McBryan T, Nelson DM, et al. Senescent cells harbour features of  
608 the cancer epigenome. *Nat. Cell Biol.* 2013;15(12):1495–506.
- 609 45. Johnstone SE, Gladyshev VN, Aryee MJ, Bernstein BE. Epigenetic clocks, aging,  
610 and cancer. *Science.* 2022;378(6626):1276–1277.
- 611 46. Zhao Y, Shao Q, Peng G. Exhaustion and senescence: two crucial dysfunctional  
612 states of T cells in the tumor microenvironment. *Cell. Mol. Immunol.* 2020;17(1):27–35.
- 613 47. Abdel-Wahab O, Gao J, Adli M, et al. Deletion of *Asxl1* results in myelodysplasia  
614 and severe developmental defects in vivo. *J. Exp. Med.* 2013;210(12):2641–2659.
- 615 48. Nagase R, Inoue D, Pastore A, et al. Expression of mutant *Asxl1* perturbs  
616 hematopoiesis and promotes susceptibility to leukemic transformation. *J. Exp. Med.*  
617 2018;215(6):1729–1747.
- 618 49. Micol J-B, Abdel-Wahab O. The role of Additional sex combs-like proteins in cancer.  
619 *Cold Spring Harb. Perspect. Med.* 2016;6(10):a026526.
- 620 50. Boultonwood J, Perry J, Pellagatti A, et al. Frequent mutation of the polycomb-  
621 associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid  
622 leukemia. *Leukemia.* 2010;24(5):1062–5.
- 623 51. Russell B, Graham, J. M. Jr. Expanding our knowledge of conditions associated with  
624 the ASXL gene family. *Genome Med.* 2013;5(2):16.
- 625 52. Bodemer C, Sauvage V, Mahlaoui N, et al. Live rubella virus vaccine long-term  
626 persistence as an antigenic trigger of cutaneous granulomas in patients with primary  
627 immunodeficiency. *Clin. Microbiol. Infect.* 2014;20(10):O656-63.
- 628 53. Zhang D, Wanat KA, Perelygina L, et al. Cutaneous granulomas associated with  
629 rubella virus: a clinical review. *J. Am. Acad. Dermatol.* 2023;
- 630 54. Buchbinder D, Hauck F, Albert MH, et al. Rubella virus-associated cutaneous  
631 granulomatous disease: a unique complication in immune-deficient patients, not limited  
632 to DNA repair disorders. *J. Clin. Immunol.* 2019;39(1):81–89.

- 633 55. Perelygina L, Icenogle J, Sullivan KE. Rubella virus-associated chronic inflammation  
634 in primary immunodeficiency diseases. *Curr. Opin. Allergy Clin. Immunol.*  
635 2020;20(6):574–581.
- 636 56. Gross M, Speckmann C, May A, et al. Rubella vaccine-induced granulomas are a  
637 novel phenotype with incomplete penetrance of genetic defects in cytotoxicity. *J. Allergy*  
638 *Clin. Immunol.* 2022;149(1):388-399 e4.
- 639 57. Hoischen A, van Bon BWM, Rodríguez-Santiago B, et al. *De novo* nonsense  
640 mutations in *ASXL1* cause Bohring-Opitz syndrome. *Nat. Genet.* 2011;43(8):729–731.  
641



642 **Table 1: Immunophenotyping of Index patient lymphocytes in early adolescence**  
643 **(10-15 years-of-age).** Red denotes high values and blue denotes low values. The \*  
644 indicates values with a reference range that is based on adult healthy controls.

Hematologic and immunologic parameters	Index Patient	Age matched Reference range
<b>T-cell subsets (Units)</b>		
CD3 <sup>+</sup> (10 <sup>9</sup> cells/L)	<b>0.374</b>	0.850-3.200
CD3 <sup>+</sup> CD4 <sup>+</sup> (10 <sup>9</sup> cells/L)	<b>0.151</b>	0.400-2.100
CD3 <sup>+</sup> CD8 <sup>+</sup> (10 <sup>9</sup> cells/L)	<b>0.208</b>	0.300-1.300
CD3 <sup>+</sup> CD4 <sup>+</sup> CD45RA <sup>+</sup> CD31 <sup>+</sup> (recent thymic emigrants) (%)	<b>2</b>	31-81
CD3 <sup>+</sup> 4 <sup>+</sup> 45RA <sup>+</sup> 27 <sup>+</sup> (naïve) (%)	<b>30</b>	37-97
CD3 <sup>+</sup> 4 <sup>+</sup> 45RA <sup>+</sup> 27 <sup>-</sup> (terminally differentiated) (%)	0.588	0.004-5.800
CD3 <sup>+</sup> 4 <sup>+</sup> 45RA <sup>-</sup> 27 <sup>-</sup> (effector memory) (%)	8.922	0.490-25
CD3 <sup>+</sup> 4 <sup>+</sup> 45RA <sup>-</sup> 27 <sup>+</sup> (central memory) (%)	61	13-76
CD4 <sup>+</sup> PD1 <sup>+</sup> (%)*	<b>60.6</b>	3.2 - 20.4
CD4 <sup>+</sup> CD57 <sup>+</sup> (%)*	2.8	0.3 - 13.9
CD3 <sup>+</sup> 8 <sup>+</sup> 45RA <sup>+</sup> 197 <sup>+</sup> 27 <sup>+</sup> (naïve) (%)	<b>1</b>	20-95
CD3 <sup>+</sup> 8 <sup>+</sup> 45RA <sup>+</sup> 197 <sup>-</sup> 27 <sup>-</sup> (terminally differentiated) (%)	60	9-65
CD3 <sup>+</sup> 8 <sup>+</sup> 45RA <sup>-</sup> 197 <sup>-</sup> 27 <sup>-</sup> (effector memory) (%)	<b>0</b>	4-100
CD3 <sup>+</sup> 8 <sup>+</sup> 45RA <sup>-</sup> 197 <sup>+</sup> 27 <sup>+</sup> (central memory) (%)	8.00	0.42-18
CD8 <sup>+</sup> PD1 <sup>+</sup> (%)*	<b>63.3</b>	4.7 – 40.7
CD8 <sup>+</sup> CD57 <sup>+</sup> (%)*	<b>64.0</b>	4.1 – 51.9
<b>B-cell subsets (Units)</b>		
CD19 <sup>+</sup> B lymphocyte absolute (10 <sup>9</sup> cells/L)	<b>0.069</b>	0.120-0.740
CD19 <sup>+</sup> CD27 <sup>+</sup> memory B-cells (%)	<b>1.3</b>	13.3-47.9
CD19 <sup>+</sup> CD27 <sup>-</sup> IgD <sup>+</sup> naïve (%)	<b>86.1</b>	57.3-82.5
CD19 <sup>+</sup> CD27 <sup>+</sup> IgM <sup>+</sup> IgD <sup>+</sup> CD38 <sup>dim</sup> CD24 <sup>+</sup> (memory, non-switched) (%)	<b>0.8</b>	4.6-18.2
CD19 <sup>+</sup> CD27 <sup>+</sup> IgM <sup>+</sup> IgD <sup>-</sup> CD38 <sup>dim</sup> CD24 <sup>-</sup> (memory, class switched) (%)	<b>0.5</b>	8.7-25.6
CD19 <sup>+</sup> IgM <sup>+</sup> CD38 <sup>++</sup> (transitional) (%)	<b>0.2</b>	1.4-13.0
CD19 <sup>+</sup> CD21 <sup>lo</sup> CD38 <sup>lo</sup> (%)	<b>65</b>	1.0-11.0
<b>Other immunological parameters (Units)</b>		
CD4 <sup>+</sup> T-cell repertoire	Normal Polyclonal Pattern	
CD8 <sup>+</sup> T-cell repertoire		
CD3 <sup>+</sup> CD8 <sup>+</sup> TCR Vβ12 (% of total CD8 cells)	<b>39.5</b>	0.33-3.33
CD3 <sup>+</sup> CD8 <sup>+</sup> TCR Vβ14 (% of total CD8 cells)	<b>18.35</b>	1.50-14.30

646 **Figure Legends**

647 **Figure 1: Clinical phenotype of a patient with biallelic ASXL1 variants.** A) Clinical  
648 timeline depicting the patient's infections requiring hospitalization in early childhood  
649 (pneumonia and primary EBV infection with bacterial pneumonia), timing of MMR  
650 vaccines, onset of cutaneous granulomas and EBV<sup>+</sup> Hodgkin lymphoma, and definitive  
651 treatment with HSCT. B) Timeline of hematologic parameters, demonstrating  
652 normal/elevated hemoglobin, declining platelet and absolute neutrophil counts, chronic  
653 macrocytosis, low/normal T-cell counts, and progressive loss of B-cells. C) Image of  
654 healing cutaneous granuloma on left knee taken in early adolescence (10-15 years of  
655 age). D) Bone marrow biopsy showing mildly hypocellular marrow and presence of a  
656 granuloma (arrowhead).

657 ANC, absolute neutrophil count; Hb, hemoglobin; HSCT, hematopoietic stem cell  
658 transplantation; MCV, mean corpuscular volume; Plt, platelets.

659 **Figure 2: Characterization of germline biallelic ASXL1 variants identified in the**  
660 **index patient.** A) Family pedigree of ASXL1 variant inheritance pattern. B) Index  
661 patient and her family's ASXL1 genotype as verified by sequencing. C) Schematic of  
662 major functional domains in ASXL1 and the positions of patient and other reported  
663 germline variants. Patient's ASXL1 variants (C111Y and S1237F, labeled red) are  
664 located outside the mutational hotspot and major functional domains. A variant linked to  
665 non-Hodgkin lymphoma (R402Q) is labeled blue, and those linked to BOS are labeled  
666 gray. D) Histograms of patient and control ASXL1 protein abundance in expanded T-  
667 cells (CD4<sup>+</sup> and CD8<sup>+</sup>) based on flow cytometry, and their respective quantification as  
668 measured over four separate experiments. E) Histogram of patient and HC ASXL1  
669 protein abundance in cultured fibroblasts using flow cytometry, and their respective  
670 quantification as measured over three separate experiments. F) Histogram of patient  
671 and HC H2AK119 ubiquitin levels in expanded CD4<sup>+</sup> and CD8<sup>+</sup> T-cells based on flow  
672 cytometry, and their respective quantification as measured over three separate  
673 experiments. Results from one representative experiment are shown in each of D, E,

674 and F. \* $P < .05$ , \*\* $P < .01$ , \*\*\* $P < .001$ , one-way analysis of variance and Dunnett's  
675 multiple comparison test.

676 **Figure 3: Patient and HC DNAm profiles and EA.** A) Volcano plot of differential  
677 DNAm patterns detected in WB and PBMCs with linear regression.  $\Delta\beta$  represents the  
678 effect size of the patient status variable after accounting for age at sample collection  
679 and sex. Magenta points indicate DMs with increased DNAm in the patient, whereas the  
680 turquoise points represent those with decreased DNAm. The vertical dark gray line  
681 represents an effect size threshold of 0.1, and the horizontal line corresponds to the  
682 statistical threshold of  $P_{adj} = .05$ . B) Venn diagram showing the overlap of DMs with  $P_{adj}$   
683  $< .05$  in WB and PBMCs. C) Enriched chromatin states based on the DMs in WB and  
684 PBMCs using the 18-state ChromHMM model. Overrepresentation analysis was used to  
685 extrapolate the significance of the enrichment. The gray dashed line corresponds to  $P_{adj}$   
686  $= .05$ . D) Horvath pan-tissue EA was calculated in WB and PBMCs with the methylclock  
687 package. HC samples are indicated in light blue, while patient samples are shown in  
688 red. The black line is the linear model best fit line. The gray area corresponds to the  
689 95% confidence interval.

690 **Figure 4: DNA methylation disturbance in expanded patient-derived T-cells and**  
691 **molecular rescue by WT ASXL1 transduction.** A) GFP signal and ASXL1 protein  
692 abundance in expanded T-cells transduced with either EV or WT ASXL1, as detected  
693 by flow cytometry. The vectors contained a GFP tag, so the transduction efficiency was  
694 represented by the GFP signal. The HC condition consisted of expanded HC T-cells  
695 with EV transduction, while the patient and rescue conditions consisted of expanded  
696 patient-derived T-cells transduced with EV or WT ASXL1, respectively. B) Biplot of PC1  
697 and PC2 generated by PCA of DNAm measured at all loci on the methylation  
698 microarray. Unrelated HC samples are labeled blue, family HCs are labeled orange,  
699 patient samples are labeled purple, and rescued samples are labeled green. C) Heat  
700 map of DMs in linear regression analysis comparing patient with unrelated and family  
701 HC samples, with the DMs in rows and samples in columns. The heat map on the left is  
702 row normalized, and that on the right shows the DNAm level (beta value). D) Venn

703 diagram showing the DMs in the *patient vs. HC* (purple) and *rescued vs. HC* (green)  
704 comparisons. The DMs were detected with thresholds of  $P_{adj} < .2$  and  $\Delta\beta > 0.1$ .  
705 E) Enriched chromatin states based on the DMs in the *patient vs. HC* (purple) and  
706 *rescued vs. HC* (green) comparisons using the 18-state ChromHMM model.  
707 Overrepresentation analysis was used to extrapolate the significance of the enrichment.  
708 The gray dashed line corresponds to  $P_{adj} = .05$ . F) Bar graph showing the differences in  
709 Horvath pan-tissue epigenetic age and chronological age of the expanded T-cells.  $*P <$   
710  $.05$ ,  $**P < .01$ ,  $***P < .001$ , one-way analysis of variance with Dunnett's multiple  
711 comparison test.

712 GFP, green fluorescent protein; Iso ctrl, isotype control


713 **Figure 5: T-cell phenotyping of the index patient.** A) T-cell flow cytometry dot plots  
714 showing CD4 T and CD8 T-cell-specific comparisons of the patient and one  
715 representative age-matched HC. Subset analyses of naïve, TCM, TEM, and TEMRA  
716 are shown in the first column, as determined by their expression of CCR7 and CD45RA.  
717 Expression levels of the T-cell exhaustion marker PD1<sup>+</sup> and senescence marker CD57<sup>+</sup>  
718 are presented in columns 2 and 3, respectively, for both CD4 and CD8 T-cells along  
719 with the expression of CD45RA. Age-matched reference ranges for quantification of  
720 different subsets are presented in Table 1. B) pSTAT5 response in the naïve CD4 T and  
721 naïve CD8 T-cell subsets of PBMCs from the patient (purple), family HC (orange), and  
722 unrelated HC (light blue) after stimulation with 1, 10, or 100 U/mL IL-2. Flow cytometry  
723 histograms of different IL-2 doses are presented on the left. pSTAT5<sup>+</sup> cells were  
724 quantified by gating after unstimulated HCs. Two different time points of patient samples  
725 are represented with different symbols: triangles (time point 1) and circles (time point 2).  
726  $**P < .01$ , unpaired *t* test at each dose followed by the Holm–Šídák multiple comparison  
727 test. C) pSTAT5 abundance in expanded T-cells from the patient and controls (HC and  
728 family) was measured by flow cytometry with gating for CD4 and CD8 T-cell subsets.  
729 Abundance was measured before and after stimulation with 1 U/mL IL-2 for 15 minutes  
730 ( $n = 3$ ). A histogram from one representative experiment is shown here. pSTAT5<sup>+</sup> cells  
731 were determined by gating at the unstimulated patient sample in each experiment.  $*P <$

732 .05, \*\* $P < .01$ , \*\*\* $P < .001$ , unpaired  $t$  test at each dose followed by the Holm–Šídák  
733 multiple comparison test.


734 FMO, fluorescence minus one; TCM, central memory T-cell; TEM, effector memory T-  
735 cell; TEMRA, effector memory RA<sup>+</sup> T-cell.

Figure 1

A




B











C







D




**Figure 2****A****B****C****D****E****F**




**Figure 3****A****B****C****D**

**Figure 4**




**Figure 5**

**A**



**B**



**C**

